Medtronic PLC $MDT Holdings Lessened by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Medtronic stake by 86.2% in the third quarter, selling 58,606 shares and retaining 9,369 shares worth approximately $808,000.
• Other major institutional investors, including BlackRock, State Street and Bank of America, increased their positions; institutions collectively own 82.06% of Medtronic’s stock.
• Medtronic reported quarterly earnings and revenue above analyst expectations, while analysts maintain a “Moderate Buy” consensus with an average price target of $102.88. The company also declared a $0.72 quarterly dividend, representing a 3.0% annualized yield.

Curated Wealth Partners LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 86.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,369 shares of the medical technology company's stock after selling 58,606 shares during the period. Curated Wealth Partners LLC's holdings in Medtronic were worth $808,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in MDT. BlackRock Inc. raised its holdings in shares of Medtronic by 0.7% in the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after acquiring an additional 838,220 shares during the last quarter. State Street Corp lifted its position in Medtronic by 2.7% in the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company's stock valued at $5,005,320,000 after acquiring an additional 1,658,301 shares in the last quarter. Bank of America Corp DE lifted its position in Medtronic by 5.4% in the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company's stock valued at $2,254,200,000 after acquiring an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company's stock valued at $1,078,321,000 after purchasing an additional 3,739,288 shares during the last quarter. Finally, WCM Investment Management LLC acquired a new position in Medtronic during the 1st quarter valued at about $965,922,000. 82.06% of the stock is owned by institutional investors.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Barclays raised Medtronic to a "hold" rating in a report on Wednesday, October 7th. Evercore set a $105.00 target price on Medtronic in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $92.00 target price on shares of Medtronic in a report on Thursday, September 3rd. UBS Group reaffirmed a "cautious" rating on shares of Medtronic in a research report on Wednesday. Finally, Stifel Nicolaus lifted their target price on Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research report on Wednesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Medtronic has an average rating of "Moderate Buy" and a consensus price target of $102.88.

Medtronic Stock Performance

Shares of MDT opened at $95.89 on Friday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The stock's fifty day moving average price is $90.87 and its two-hundred day moving average price is $84.95. The firm has a market cap of $122.66 billion, a PE ratio of 23.62, a PEG ratio of 2.15 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period in the previous year, the business earned $1.26 EPS. Medtronic's revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. Medtronic's dividend payout ratio is 70.94%.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic completed the separation of MiniMed Group, which began trading independently as MiniMed Nasdaq: MMED. The transaction gives Medtronic a more focused portfolio and could allow both companies to pursue more targeted growth and capital-allocation strategies. Medtronic Completes Separation of MiniMed Group
• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s Best Inventions of 2026 list. The recognition supports the company’s innovation narrative and may improve visibility for newer products, although it does not directly change near-term earnings. Medtronic Named to TIME Best Inventions List
• Neutral Sentiment: Analysts offered mixed but generally cautious views: Barclays initiated coverage at Equal Weight, while Piper Sandler assigned a Hold rating. These calls suggest analysts see potential from improving sales growth but limited near-term upside after the stock’s recent advance. Barclays Initiates Coverage
• Neutral Sentiment: Recent coverage highlights Medtronic’s stronger fiscal first-quarter results and raised annual outlook, but also notes that the MiniMed separation changes the earnings mix investors are buying. The key question is whether the remaining business can sustain faster growth. Trefis Analysis of Medtronic
• Negative Sentiment: Exchange-offer results and reported ETF sales of approximately $222.5 million indicate meaningful trading and possible short-term selling pressure as investors adjust positions following the MiniMed separation. ETF Sales of Medtronic

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.